Takeda’s Pipeline Has Potential to Contribute Significantly to
Revenue Growth Over Next Decade
As part of our December Wave 1 Pipeline Market Opportunity Call, Takeda business executives and scientific leadership provided an update on our pipeline portfolio, which is expected to be a source of significant growth over the next decade. Our Wave 1 pipeline is reflective of our vision to discover and deliver life-transforming treatments guided by our commitment to patients, our people and the planet.
Keeping the Innovation Bar High
Our Wave 1 pipeline includes 12 unique New Molecular Entities (NMEs), representing potential best-in-class/first-in-class therapies targeted for launch by FY2024. All 12 of these NMEs have anticipated near-term late-development milestones, pivotal data readouts or pivotal study starts. As of today, five have received Breakthrough Therapy designation and three were granted fast track designation by the U.S. Food and Drug Administration (FDA). In addition, one program received designation under the SAKIGAKE Designation System by the Japanese Ministry of Health, Labour and Welfare and another program was the first breakthrough designation granted by the China Food and Drug Administration to a multinational biopharmaceutical company.
Beyond the Wave 1 Pipeline
Beyond the Wave 1 pipeline, our world-class, state-of-the-art research engine, comprised of internal research capabilities and more than 200 active partnerships, is rapidly advancing a steady stream of next-generation therapies in Wave 2 of our pipeline that will provide sustained growth in FY2025 and beyond. These Wave 2 pipeline programs are designed to provide transformative or curative potential for targeted populations with high unmet need across core therapeutic areas. They are based on targets with strong human validation, represent diverse modalities and leverage new platform capabilities in cell therapy, gene therapy and data sciences.
To access a replay of our Wave 1 Pipeline Market Opportunity Call, including presentation slides with the latest data and updates on two Wave 1 programs - TAK-721 and TAK-003 - visit www.qiqiselu.cn/investors/ir-events.
View our press release.